Latest Breaking News On - Sysmex inostics gmb - Page 1 : vimarsana.com

In-Depth Analysis of Next Generation Sequencing (NGS) Tests, 2023 Clinical Pipeline Report

/PRNewswire/ -- The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path...

In-Depth Analysis of Next Generation Sequencing (NGS) Tests, 2023 Clinical Pipeline Report

Cancer Biopsy Market is projected to increase at a CAGR of around 18% from 2023 to 2033

The Cancer Biopsy market revenues were estimated at US$ 22.2 Bn in 2022 and is anticipated to grow at a CAGR of 18% from 2023-2033, according to a recently published Future Market Insights report. By the end of 2033, the market is expected to reach US$ 131.4 Bn.The increasing elderly populace, along with the rise in...

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

/PRNewswire/ -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid...

Cancer Biopsy Market Size To Reach $44.51 Billion By 2027 | CAGR: 11.13%: Grand View Research, Inc.

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients News provided by Share this article Share this article BALTIMORE, April 10, 2021 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster "Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients" at the 112 th Annual Meeting of the American Association for Cancer Research on April 10, 2021, from 8:30 AM - 11:59 PM Eastern Daylight Time (EDT). In a recent collaborative study, Johns Hopkins University School of Medicine and Sysmex Inostics' researchers showed that the next-generation sequencing (NGS)-based liquid biopsy SafeSEQ NSCLC panel delivers equivalent performance with broader genomic coverage than testing with OncoBEAM™ digital PCR (dPCR). OncoBEAM technology is widely considered a gold standard for high sensitivity molecular testing and continues to be one of the most sensitive dPCR approaches. 

Sysmex has launched Plasma-SeqSensei liquid biopsy RUO kits in EMEA

Product News: Sysmex has launched Plasma-SeqSensei liquid biopsy RUO kits in EMEA 01 Apr 2021 Sysmex Europe GmbH, together with Sysmex Inostics GmbH, has announced that they will launch the Plasma-SeqSensei™ liquid biopsy research use only (RUO) kits for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma and thyroid cancer.  Liquid biopsy detects material in body fluids to assess the extent of disease, most often used for the detection of cancerous material in plasma. Though several molecular techniques are used, next generation sequencing is considered to be the most important method to detect minute amounts of circulating tumour DNA (ctDNA). In contrast to tissue biopsy, which is not always obtainable and much more invasive, liquid biopsy is well-suited for clinical research purposes due to its less invasive nature, high concordance to tissue samples in many cancers and real time information available.